Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 6/2013

01-06-2013 | Original Research Paper

Effect of chlorogenic acid on LPS-induced proinflammatory signaling in hepatic stellate cells

Authors: Haitao Shi, Lei Dong, Xiaoyan Dang, Yaping Liu, Jiong Jiang, Yan Wang, Xiaolan Lu, Xiaoyan Guo

Published in: Inflammation Research | Issue 6/2013

Login to get access

Abstract

Objective and design

This study was aimed at investigating the effect of chlorogenic acid (CGA) on lipopolysaccharide (LPS)-induced proinflammatory signaling in hepatic stellate cells (HSCs).

Methods

An immortalized rat HSC line was cultured in vitro and treated with LPS in the absence or presence of CGA. Reactive oxygen species (ROS) production in the HSCs was monitored by flow cytometer using DCFH-DA. The protein expression levels of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), nuclear factor-κB (NF-κB), and p-IκB-α were determined by Western blot. The mRNA expression levels of TLR4, MyD88, monocyte chemotactic protein 1(MCP-1), and interleukin 6 (IL-6) were detected by RT-PCR. The levels of MCP-1 and IL-6 in the culture supernatant of HSCs were measured by ELISA.

Results

CGA had no effect on expression of TLR4 and MyD88. However, the treatment of CGA can inhibit LPS-induced production of ROS in HSCs. Meanwhile, CGA can inhibit LPS-induced nuclear translocation of NF-κB and IκB-α phosphorylation in HSCs, as well as NAC (a ROS scavenger). The mRNA expression and the levels of MCP-1 and IL-6 in the culture supernatant of the HSCs in this study were elevated by LPS stimulation and inhibited by CGA treatment, as well as NAC and PDTC (a NF-κB inhibitor).

Conclusion

Our results indicate that CGA can efficiently inhibit LPS-induced proinflammatory responses in HSCs and the anti-inflammatory effect may be due to the inhibition of LPS/ROS/NF-κB signaling pathway.
Literature
1.
Bataller R, Brenner DA. Liver fibrosis. J Clin Investig. 2005;115:209–18.PubMed
2.
Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol and Hepatol. 2010;7:425–36.CrossRef
3.
Fallowfield JA. Therapeutic targets in liver fibrosis. Am J Physiol-Gastrointest Liver Physiol. 2011;300:G709–15.PubMedCrossRef
4.
5.
Saile B, Ramadori G. Inflammation, damage repair and liver fibrosis—role of cytokines and different cell types. Z Gastroent. 2007;45:77–86.CrossRef
6.
Pinzani M, Macias-Barragan J. Update on the pathophysiology of liver fibrosis. Expert Rev Gastroenterol Hepatol. 2010;4:459–72.PubMedCrossRef
7.
O’Neill LA. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol. 2003;3:396–403.PubMedCrossRef
8.
Zhu JK, Mohan C. Toll-like receptor signaling pathways-therapeutic opportunities. Mediat Inflamm. 2010. Art ID 781235.
9.
Aoyama T, Paik YH, Seki E. Toll-like receptor signaling and liver fibrosis. Gastroenterol Res Pract. 2010. Art ID 192543.
10.
Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, et al. Endotoxemia in patients with chronic liver-diseases—relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol. 1995;22:165–72.PubMedCrossRef
11.
Parlesak A, Schafer C, Schutz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol. 2000;32:742–7.PubMedCrossRef
12.
Choi Y, Jeon WK, Hwang SJ, Kim BI, Sohn CI, Park DI, et al. The Role of the Gut Barrier Function in the Pathophysiology of Viral Liver Cirrhosis. Hepato-Gastroenterol. 2011;58:1244–7.
13.
Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology. 2008;48:322–35.PubMedCrossRef
14.
Brun P, Castagliuolo I, Pinzani M, Palu G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol-Gastroint Liver Physiol. 2005;289:G571–8.CrossRef
15.
Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003;37:1043–55.PubMedCrossRef
16.
Thirunavukkarasu C, Watkins SC, Gandhi CR. Mechanisms of endotoxin-induced NO, IL-6, and TNF-alpha production in activated rat hepatic stellate cells: role of p38 MAPK. Hepatol. 2006;44:389–98.CrossRef
17.
Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324–32.PubMedCrossRef
18.
Feng RT, Lu YJ, Bowman LL, Qian Y, Castranova V, Ding M. Inhibition of activator protein-1, NF-kappa B, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J Biol Chem. 2005;280:27888–95.PubMedCrossRef
19.
Zhang X, Huang H, Yang TT, Ye Y, Shan JH, Yin ZM, et al. Chlorogenic acid protects mice against lipopolysaccharide-induced acute lung injury. Inj Int J Care Inj. 2010;41:746–52.
20.
Kono Y, Kobayashi K, Tagawa S, Adachi K, Ueda A, Sawa Y, et al. Antioxidant activity of polyphenolics in diets Rate constants of reactions of chlorogenic acid and caffeic acid with reactive species of oxygen and nitrogen. Biochim Biophys Acta. 1997;1335:335–42.PubMedCrossRef
21.
Shi HY, Dong L, Bai YH, Zhao JH, Zhang Y, Zhang L. Chlorogenic acid against carbon tetrachloride-induced liver fibrosis in rats. Eur J Pharmacol. 2009;623:119–24.PubMedCrossRef
22.
Xu YX, Chen JW, Yu XA, Tao WW, Jiang FR, Yin ZM, et al. Protective effects of chlorogenic acid on acute hepatotoxicity induced by lipopolysaccharide in mice. Inflamm Res. 2010;59:871–7.PubMedCrossRef
23.
Shan JH, Fu J, Zhao ZH, Kong XQ, Huang H, Luo L, et al. Chlorogenic acid inhibits lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 cells through suppressing NF-kappa B and JNK/AP-1 activation. Int Immunopharmacol. 2009;9:1042–8.PubMedCrossRef
24.
Wang BB, Cheng JY, Gao HH, Zhang Y, Chen ZN, Bian HJ. Hepatic stellate cells in inflammation-fibrosis-carcinoma axis. Anat Rec. 2010;293:1492–6.CrossRef
25.
Vogel S, Piantedosi R, Frank J, Lalazar A, Rockey DC, Friedman SL, et al. An immortalized rat liver stellate cell line (HSC-T6): a new cell model for the study of retinoid metabolism in vitro. J Lipid Res. 2000;41:882–93.PubMed
26.
Lebel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2′, 7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol. 1992;5:227–31.PubMedCrossRef
27.
Choi HK, Pokharel YR, Lim SC, Han HK, Ryu CS, Kim SK, et al. Inhibition of liver fibrosis by solubilized coenzyme Q10: Role of Nrf2 activation in inhibiting transforming growth factor-beta 1 expression. Toxicol Appl Pharmacol. 2009;240:377–84.PubMedCrossRef
28.
Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radical Biol Med. 2010;48:1121–32.CrossRef
29.
Wu J, Meng ZJ, Jiang M, Zhang EJ, Trippler M, Broering R, et al. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology. 2010;129:363–74.PubMedCrossRef
30.
31.
DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 1997;388:548–54.PubMedCrossRef
32.
Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The I kappa B kinase complex (IKK) contains two kinase subunits, IKK alpha and IKK beta, necessary for I kappa B phosphorylation and NF-kappa B activation. Cell. 1997;91:243–52.PubMedCrossRef
33.
Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol. 1998;152:423–30.PubMed
34.
Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Semin Liver Dis. 2010;30:215–25.PubMedCrossRef
35.
Seki E, De Minicis S, Inokuchi S, Taura K, Miyai K, Van Rooijen N, et al. CCR2 Promotes Hepatic Fibrosis in Mice. Hepatology. 2009;50:185–97.PubMedCrossRef
36.
Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology. 1999;29:140–8.PubMedCrossRef
37.
Tsuruta S, Nakamuta M, Enjoji M, Kotoh K, Hiasa K, Egashira K, et al. Anti-monocyte chemoattractant protein-1 gene therapy prevents dimethylnitrosamine-induced hepatic fibrosis in rats. Int J Mol Med. 2004;14:837–42.PubMed
38.
Kayano K, Okita K. Does IL-6 regulate liver fibrosis/cirrhosis directly and indirectly? J Gastroenterol. 2000;35:250–1.PubMedCrossRef
39.
Choi I, Kang HS, Yang Y, Pyun KH. IL-6 induces hepatic inflammation and collagen-synthesis in vivo. Clin Exp Immunol. 1994;95:530–5.PubMedCrossRef
40.
Asehnoune K, Strassheim D, Mitra S, Kim JY, Abraham E. Involvement of reactive oxygen species in Toll-like receptor 4-dependent activation of NF-kappaB. J Immunol. 2004;172:2522–9.PubMed
41.
Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappaB. J Immunol. 2004;173:3589–93.PubMed
Metadata
Title
Effect of chlorogenic acid on LPS-induced proinflammatory signaling in hepatic stellate cells
Authors
Haitao Shi
Lei Dong
Xiaoyan Dang
Yaping Liu
Jiong Jiang
Yan Wang
Xiaolan Lu
Xiaoyan Guo
Publication date
01-06-2013
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 6/2013
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-013-0610-7

Other articles of this Issue 6/2013

Inflammation Research 6/2013 Go to the issue

Original Research Paper

Lipopeptides rather than lipopolysaccharide favor the development of dendritic cell dysfunction similar to polymicrobial sepsis in mice

Original Research Paper

Antagonism of the histamine H4 receptor reduces LPS-induced TNF production in vivo

Short Communication

Transcription factor STAT1 gene polymorphism is associated with the development of severe forms of periodontal disease

Original Article

Suppression of Toll-like receptor 4 activation by endogenous oxidized phosphatidylcholine, KOdiA-PC by inhibiting LPS binding to MD2

Original Research Paper

Concentration dependent anti-inflammatory effects thrombin on polyphosphate-mediated inflammatory responses in vitro and in vivo

Review

Polymorphonuclear neutrophils and instability of the atherosclerotic plaque: a causative role?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits